Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

Trial ID: NCT05960565

Interventional - Phase 2 - Terminated

The investigators will study the effect of microdoses of glucagon at the site of subcutaneous insulin injection. The investigators have unpublished data from anesthetized pigs indicating a major enhancement of insulin absorption.

Conditions

• Type 1 Diabetes

Interventions

• Glucagon

Eligibility

Inclusion criteria

• 1: Type 1 diabetes for at least 1 year. 2. Age 18
• 70 years. 3. Last known HbA1c \<86 mmol/mol. 4. Treated with continuous subcutaneous insulin infusion (CSII) by an insulin pump or multiple daily insulin injections (MDII).

Exclusion criteria

• Pregnant women or women trying to conceive.
• 2. Any chronic disease, including psychiatric illness, judged incompatible with participation in the study.
• 3. Unfit for participation for any reason judged by the investigators.
• 4. Known hypersensitivity to glucagon or any of the excipients of the drug formulation.
• 5. Known phaeochromocytoma. -

Sponsor

St. Olavs Hospital

Source: Clinicaltrials.gov

Search more clinical trials on myTomorrows